Safety Considerations Associated with Development and Clinical Application of Lentiviral Vector Systems for Gene Transfer

Buchschacher, Jr., Gary L.
January 2004
Current Genomics;Jan2004, Vol. 5 Issue 1, p19
Academic Journal
Lentiviral vector systems continue to be developed and investigated for possible use in clinical gene transfer studies and for application as potential gene therapies. These vector systems, as a new technology and potentially novel medical therapy, raise a number of safety concerns, both real and perceived. Careful and thorough characterization of the lentiviral vector systems and of how they might interact with cellular genomes and other pathogens is necessary in order to maximize the safety of this technology as it is developed and the safety of both individuals undergoing gene transfer procedures and the general population. Identification of potential safety concerns should not prevent or unnecessarily delay the development of lentiviral vectors for use in clinical gene transfer, but suggest areas of investigation where it would be wise to allocate resources and effort.


Related Articles

  • Lentiviral vectors: Lentiviral vectors for the treatment of Wiskott-Aldrich syndrome. Nienhuis, A. W. // Gene Therapy;Apr2005, Vol. 12 Issue 7, p555 

    Presents the study on the effectiveness of lentiviral vectors for the treatment of Wiskott-Aldrich syndromes (WAS). Speculation on the possibility of treating blood-forming tissues through the transfer of genes into stem cells to regenerate bone marrow and lymphoid organs; Overview of the WAS...

  • Intradermal Injection of Lentiviral Vectors Corrects Regenerated Human Dystrophic Epidermolysis Bullosa Skin Tissue in Vivo Woodley, David T.; Keene, Douglas R.; Atha, Tom; Huang, Yi; Ram, Ramin; Kasahara, Noriyuki; Chen, Mei // Molecular Therapy;Aug2004, Vol. 10 Issue 2, p318 

    Dystrophic epidermolysis bullosa (DEB) is a family of inherited mechanobullous disorders caused by mutations in the gene, COL7A1, that codes for type VII, (anchoring fibril), collagen, which is critical for epidermal–dermal adherence. Most gene therapy approaches have been ex vivo,...

  • Risks and Benefits of Gene Therapy. Noguchi, Philip // New England Journal of Medicine;1/16/2003, Vol. 348 Issue 3, p193 

    Comments on gene-therapy trials and the outlook for a cure of genetic disease. Reference to research in Europe into severe combined immunodeficiency using a modified retrovirus to insert a corrective gene into the host genome; Discussion of a report by Hacein-Bey and colleagues about a serious...

  • HIV-1 Vectors: Fulfillment of Expectations, Further Advancements, and Still A Way To Go. Cockrell, Adam S.; Kafri, Tal // Current HIV Research;Oct2003, Vol. 1 Issue 4, p419 

    The ability of lentiviral vectors to transduce and stably integrate their genomes into non-dividing cells was the major reason for the development of the HIV-1 based vector gene delivery system. The first VSVG pseudotyped lentiviral vectors fulfilled these expectations by ferrying large genetic...

  • Immunodeficiencies: Injecting some safety into SCID gene therapy? Candotti, F.; Roifman, C.; Puck, J. M. // Gene Therapy;May2006, Vol. 13 Issue 9, p741 

    The article highlights a study which shows that in situ corrective gene transfer can restore T cell development in a form of severe combined immunodeficiency. The author discusses the implication of the study on gene therapy for human T cell deficiencies. The author also highlights the...

  • Can the Use of HIV-1 Derived Gene Transfer Vectors for Clinical Application be Justified? Fuller, M.; Anson, D.S. // Current Gene Therapy;Mar2004, Vol. 4 Issue 1, p65 

    Vectors derived from human immunodeficiency virus type 1 (HIV-1) are an attractive option for many gene therapy applications as they can transduce non-cycling cell populations, and can integrate their genome into the host cell chromosome. The rationale underlying the design of most retroviral...

  • Prospects for the Therapeutic Application of Lentivirus-Based Gene Therapy to HIV-1 Infection. Yamamoto, Takuya; Tsunetsugu-Yokota, Yasuko // Current Gene Therapy;Feb2008, Vol. 8 Issue 1, p1 

    Highly active antiretroviral therapy is not sufficient to fully control HIV replication and problems of side effects and escape mutation have emerged. Current prophylactic and therapeutic vaccine strategies appear to be unable to confer full protection. However, given the rapid recent progress...

  • Vector integration: Location, location, location. Mok, H P; Lever, A M L // Gene Therapy;Jan2005, Vol. 12 Issue 1, p1 

    Reports that a new analysis of vector integration has shown how integration site varies among three different groups of retroviruses. Case of murine, avian and human retroviruses; Factors guiding the integration event; Implications for gene therapy.

  • Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport element. Mautino, M R; Keiser, N; Morgan, R A // Gene Therapy;Aug2000, Vol. 7 Issue 16, p1421 

    The development of lentiviral vectors that use Rev-independent mechanisms of nuclear export for their genomic RNA could facilitate the construction of novel anti-HIV vectors. We have improved the titers of Rev-independent lentiviral vectors having the SRV-1 CTE by mutating the major splice donor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics